Open Beta
TREN
MetriLume
TREN

US marketsNAGE

SEC-sourced researchBeta

NAGE

Niagen Bioscience, Inc.

Company comparison ↗

Data passport

CIK
0001386570
Exchange
Nasdaq
Business activity
— · SIC 2833
Financial inputs
6/6
Filing date
Mar 4, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 99,597,000.0000 USD; December 2025: 129,423,000.0000 USD129.4M USD0 USD0December 2024December 2025
NAGE · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202499,597,000.0000Mar 4, 2026
December 2025129,423,000.0000Mar 4, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025129,423,000.000017,382,000.000013,504,000.0000106,406,000.000029,873,000.0000Mar 4, 2026
December 202499,597,000.00008,550,000.000012,109,000.000068,278,000.000022,184,000.0000Mar 4, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$129.42MDecember 2025Mar 4, 202610-K
Previous period revenueRevenues$99.6MDecember 2024Mar 4, 202610-K
Net incomeNetIncomeLoss$17.38MDecember 2025Mar 4, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities$13.5MDecember 2025Mar 4, 202610-K
Total assetsAssets$106.41MDecember 2025Mar 4, 202610-K
Total liabilitiesLiabilities$29.87MDecember 2025Mar 4, 202610-K

New filings

Explore methodology ↗